Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | BRD2 | P25440 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1682032 | 0.90 | PIK3CD (0.50) | PIK3CDMEN1KMT2APOLBGAA | |
| SCHEMBL12148577 | 0.80 | GAA (0.50) | PIK3CDMEN1KMT2APOLBGAA | |
| SCHEMBL13622584 | 0.79 | PIK3CD (0.41) | PIK3CDPOLBGAAALDH1A1TSHR | |
| SCHEMBL10972607 | 0.79 | PIK3CD (0.41) | PIK3CDMEN1KMT2APOLBTSHR | |
| SCHEMBL14606115 | 0.79 | PIK3CD (0.41) | PIK3CDMEN1KMT2APOLBGAA | |
| SCHEMBL14268183 | 0.77 | PIK3CD (0.44) | PIK3CDMEN1KMT2APOLBGAA | |
| SCHEMBL8295107 | 0.74 | PIK3CD (0.47) | PIK3CDMEN1KMT2APOLBGAA | |
| SCHEMBL13791862 | 0.73 | PIK3CD (0.37) | PIK3CDMEN1KMT2APOLBTSHR | |
| SCHEMBL1303006 | 0.73 | PIK3CD (1.00) | PIK3CDMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL15894720 | 0.73 | PIK3CD (0.44) | PIK3CDGAAALDH1A1CASP6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170247725-A1 | IN VIVO AND IN VITRO OLEFIN CYCLOPROPANATION CATALYZED BY HEME ENZYMES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-08-31 | — | — | US | disclosed |
| US-9493799-B2 | In vivo and in vitro olefin cyclopropanation catalyzed by heme enzymes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160032330-A1 | P-450-CATALYZED ENANTIOSELECTIVE CYCLOPROPANATION OF ELECTRON-DEFICIENT OLEFINS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160002682-A1 | IN VIVO AND IN VITRO OLEFIN CYCLOPROPANATION CATALYZED BY HEME ENZYMES | UNITED STATES DEPARTMENT OF ENERGY | 2016-01-07 | — | — | US | disclosed |
| US-9150414-B2 | Nanocomposite and dispersion comprising the same | KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) | 2015-10-06 | — | — | US | disclosed |
| US-8993262-B2 | In vivo and in vitro olefin cyclopropanation catalyzed by heme enzymes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140242647-A1 | IN VIVO AND IN VITRO OLEFIN CYCLOPROPANATION CATALYZED BY HEME ENZYMES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-08-28 | — | — | US | disclosed |
| US-20120053288-A1 | NANOCOMPOSITE AND DISPERSION COMPRISING THE SAME | KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) | 2012-03-01 | — | — | US | disclosed |
| US-7619094-B2 | Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | SCHERING CORPORATION (US) | 2009-11-17 | — | — | US | disclosed |
| US-7619094-B2 | Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | SCHERING CORPORATION (US) | 2009-11-17 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
| US-7173057-B2 | Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus | SCHERING CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173057-B2 | Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus | SCHERING CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2005021584-A2 | NOVEL PEPTIDOMIMETIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | PREP, PRSS1, P4HB | PIK3CD 850/4885MEN1 4705/4885KMT2A 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.